Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Calixar, Regeneron join forces
June 2019
SHARING OPTIONS:

LYON, France—An exclusive licensing agreement has been struck between Calixar SAS and Regeneron Pharmaceuticals Inc. under which Regeneron gains exclusive rights to Calixar’s technology and experience to aid in the discovery of antibodies against an undisclosed target in certain therapeutic areas. Calixar stands to receive upfront and milestone payments under this deal, though specific financial terms were not released.
 
“This agreement is a key milestone for our collaboration with Regeneron as well as for our broader approach of using the best innovations to achieve the best biochemistry,” Emmanuel Dejean, CEO of Calixar, commented in a press release. “It confirms the biopharma industry’s focus on fully native, functional therapeutic targets for the development of high-quality antibodies and lead candidates with the optimal chance of becoming future blockbusters that address unmet medical needs.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.